If you invested in BLLN and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses »
CLASS PERIOD
N/A
LEAD PLAINTIFF DEADLINE
N/A
STOCK SYMBOL
NASDAQ: BLLN
CONTACT
844-916-0895
[email protected]
BillionToOne is a medical diagnostics company that has developed technology to count individual DNA molecules. The company uses this technology mainly in prenatal testing, through its UNITY tests. These tests use a simple blood draw from the mother to check whether a baby is at risk for inherited conditions such as sickle cell disease and cystic fibrosis.
Prenatal testing is BillionToOne’s core business. In the quarter ended September 30, 2026, it made up about 85% of the company's $122 million in total revenue. BillionToOne usually gets paid after it delivers test results, by billing the patient's insurer, Medicaid, Medicare, the patient directly, or some combination of them.
Fuzzy Panda raised several potential concerns in its November 18 report. Two of its claims are backed by documents and point to potential regulatory risk, which it says are not sufficiently disclosed within BillionToOne’s SEC filings. First, a Tennessee Medicaid fraud referral and patient cost caps given without having checked patient income. Second, Fuzzy Panda claims the company has overbilled and, as a result, False Claims Act penalties could exceed $1.2 billion and put “~80% of EBITDA at risk of going away.”
In response, the price of BillionToOne shares fell significantly lower on November 18.
FREQUENTLY ASKED QUESTIONS ABOUT THE CASE
- What is the BLLN investigation about?
-
We are focused on the report’s allegations and, if true, whether BillionToOne may have violated the securities laws.
WHAT SHOULD I DO?
- I worked at BLLN. What should I do?
-
If you were an employee of BLLN, you may have valuable information that could be relevant to the investigation. Hagens Berman is one of the nation’s top whistleblower law firms, and has successfully represented many individuals who come forward with information regarding corporate malfeasance. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, contact Reed Kathrein at 844-916-0895 or [email protected].
- There are multiple law firms participating, do I need to contact all of them?
-
No, you do not need to contact all participating law firms. Generally, class-action investigations and lawsuits are consolidated into a single case to streamline the legal process, and attorneys from only a few law firms are selected to serve in a leadership role on the consolidated case. Hagens Berman has a proven track record of being appointed to leadership roles in complex, multidistrict litigation regarding investor fraud and other consumer rights issues, and your claim will be handled by attorneys who have helped secure approximately $325 billion in class-action settlements on behalf of individuals who have suffered due to corporate malfeasance and the wrongdoing of other powerful institutions.
AM I ELIGIBLE?
- What is the threshold amount to be eligible? What are “substantial” losses?
-
The threshold amount and the definition of "substantial" losses may vary depending on a number of factors specific to the case, including the size of the company, market cap, shares outstanding and who holds them and the damages alleged by the fraud. In general, to be eligible to participate in a class-action lawsuit, you must be able to demonstrate that you suffered financial losses as a result of the alleged wrongdoing and that your losses meet the criteria set by the court or law firm. Fill out the form and submit your losses.
CAN I PARTICIPATE?
- Am I affected? What do I need to do to participate?
-
If you were an investor in BLLN, you may be affected and eligible to participate in the case. To determine your eligibility and potential involvement, fill out the form and submit your losses.
- Can any BLLN investor participate?
-
In most class-action investigations and cases, any investor who meets the eligibility criteria, including purchasing the shares during the relevant period, can participate, regardless of the size of their investment. Fill out the form to find out your rights.
- I bought on a non-U.S. Exchange. Can I participate?
-
No. This investigation only covers shares bought on a U.S. exchange, i.e. NASDAQ or NYSE. Fill out the form to find out your rights.
- Am I included if I still hold my shares, or do I need to sell to participate?
-
Participation is based on purchasing shares during the relevant period, rather than your current holdings. Accordingly, you do not need to sell to participate. Fill out the form to find out your rights.